



November 5, 2019
Gene Techno Science Co., Ltd.
Code: 4584 (TSE Mothers)
Masaharu Tani, President & CEO

Announcement of Academia-industry Collaboration with Showa University School of Medicine for a Development of Treatments in Cell Therapy Field using Stem Cells from Human Exfoliated Deciduous Teeth

Tokyo, November 5, 2019 – Gene Techno Science Co., Ltd. (“GTS”) executed an agreement for academia-industry collaboration (“this agreement”) with Showa University School of Medicine (“Showa University”) to develop new therapeutic treatments in cell-therapy field using Stem cell from exfoliated deciduous teeth (“SHED”).

As informed with “Announcement of Joint Research Agreement with Showa University School of Medicine for a Development of Treatments for Bone-related Diseases using Stem Cells from Human Exfoliated Deciduous Teeth” on September 10, GTS and Showa University have already started concrete activities, and Showa University highly valued the characteristics and advantages of our SHED which are different from other mesenchymal stem cells. As a result of discussions for the possibility of further collaborative research and business development, we agreed that exploring the potential of SHED more than the bone-related diseases will contribute to the enhancement of cell therapy in Japan, and this led to the conclusion of this agreement. With the development of therapeutic treatment for the diseases which treatment methods have not been established or not effective enough by fully utilizing the characteristics of SHED, we will seek to improve our values and contribute to society.

1. Purpose of this agreement

This agreement aims to develop new therapeutic treatment in cell therapy business with the collaboration of expertise in research and clinical practice in broad range of specialized fields of Showa University and SHED that forms the foundation of our cell therapy business.

2. Outline of counterparties to this agreement

1. Name	Showa University School of Medicine
2. Location	1-5-8, Hatanodai, Shinagawa-ku, Tokyo
3. Representative	Tadashi Hisamitsu

3. Future outlook

The impact on the business results for the fiscal year ending March 2020 is expected to be minimal.

About Gene Techno Science Co., Ltd.

GTS announced GTS 3.0 “Biotech Engineering Company, striving for value creation” a new business stage starting from this fiscal year, which targeted the pediatric disease in addition to the areas GTS has been engaged in such as the orphan disease and intractable disease. By leveraging the knowhow and expertise about biotechnology acquired in the past business activities, GTS is working on the development and provision of new medicines and therapeutic treatment for the purpose of achieving comprehensive healthcare solutions for the patients suffering from these diseases as well as families and caregivers.

Contact:

Gene Techno Science Co., Ltd.

Tel: +81-3-6222-9547 Mail: info@g-gts.com